Safety Profile and Issues of Subcutaneous Immunotherapy in The Treatment of Children with Allergic Rhinitis

• Main Authors: Anang Endaryanto, -, Ricardo Adrian Nugraha, -
• Format: Article PeerReviewed
• Language: English; English; English; English
• Published: MDPI Multidisciplinary Digital Publishing Institute 2022
• Subjects: R Medicine (General); RJ Pediatrics
• Online Access: https://repository.unair.ac.id/116222/1/C1-Artikel.pdf; https://repository.unair.ac.id/116222/3/C1-Similarity.pdf; https://repository.unair.ac.id/116222/4/C1-Bukti%20Korespondensi.pdf; https://repository.unair.ac.id/116222/5/Kadep.pdf; https://repository.unair.ac.id/116222/; https://www.mdpi.com/2073-4409/11/9/1584/htm; https://doi.org/10.3390/cells11091584
• Institution: Universitas Airlangga

This study aims to evaluate safety issues of house dust mite subcutaneous immunotherapy (SCIT) among allergic rhinitis (AR) children. A retrospective cohort study was done between 2015 and 2020 to investigate the side effects of SCIT among AR children caused by a house dust mite allergy. Among 1098 patients who received house dust mite subcutaneous immunotherapy injections, 284 patients (25.87%) had side effects (SE). SE were found to be 699 times higher or in 2.27% of the 30,744 subcutaneous immunotherapy injections. A total of 17.9% of the patients had local SE during SCIT administration. Systemic side effects occurred in 8.38% of children receiving SCIT and in 0.53% of the total population who received SCIT injections. Only 2/92 (2.18%) of patients suffered an allergic reaction within 30 minutes of injection and these patients responded well to antiallergic medication. Severe anaphylaxis occurred in 0.091% of the 1098 patients in the SCIT group and in 0.0033% of the 30,774 SCIT injections. Systemic SE after SCIT occurred in 8.38% of patients receiving SCIT or 0.53% of the total number of SCIT injections. Anaphylactic episodes occurred in 16 patients (1.46%) and 15 patients (1.37%) who had first and second episodes. One severe attack was found and it was resolved with adrenaline. This study demonstrates that in pediatric patients with AR who received HDM SCIT for 18 months with high adherence, some experienced significant local SE and systemic SE caused by SCIT, but this did not interfere with the course of AR treatment or the effectiveness of SCIT.